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70 Poster Session-Ibe given post ASCT; however, neuropathy is a significant common
toxicity that required patients to stop therapy. Longer follow-up is
needed to determine the duration of benefit of BLT-Dmaintenance.
With a median follow-up of 42.5 months, the majority of patients re-
main alive without evidence of disease progression.188
PERIPHERAL BLOOD CD34 COUNT CAN PREDICT SUCCESSFUL PROGEN-
ITOR CELL MOBILIZATION IN POOR MOBILIZIERS TREATED WITH
PLERIXAFOR AND G-CSF
Micallef, I.N.1, Maurer, M.2, Ansell, S.M.1, Buadi, F.1, Dispenzieri, A.1,
Gastineau, D.A.1, Gertz, M.A.1, Hayman, S.R.1, Hogan, W.J.1,
Inwards, D.J.1, Johnston, P.B.1, Kumar, S.1, Lacy, M.Q.1, Litzow, M.R.1,
Porrata, L.F.1, Winters, J.L.3, Marzolf, M.1, Shaw, T.1, Calandra, G.4
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Background:The failure rate for CD341 cell mobilization varies
from 5% in MM to 30% in NHL and HD.
Methods:We report the results of a single center experience with
plerixafor1G-CSF as re-mobilization in patients whom a prior mo-
bilization has failed. Mobilization failure was defined as inability to
collect 2  106 CD341 cells/kg or inability to achieve a peripheral
blood CD341 cells/ml of $10 and not apheresed. Re-mobilization
consisted of G-CSF at 10mcg/kg/day sq on days 1–4 plus plerixafor
240 mcg/kg/day sq on the evening of day 4. Both drugs were contin-
ued daily until a goal of 5  106 CD341 cells/kg was reached or
a maximum of 7 aphereses. Apheresis began on day 5 regardless of
the peripheral blood (pb) CD 341 cells/ml. PB CD341 was corre-
lated to CD341 harvested. In addition, we sought to determine if
there was a pb CD341 count pre or post plerixafor that would pre-
dict for a successful harvest of either 2 or 5 106 CD341 cells/kg.
Results: Baseline demographics were as follows: 54 patients, 25
females: 29 males; 29 NHL, 15 MM, 6 HD and 4 AL amyloidosis.
Median age was 64 years (range 30–76). Prior mobilization was
predominantly G-CSF alone. Median time from prior mobilization
to re-mobilization was 0.7 months (range 0.4–33 months). The me-
dian pb CD341 cells/ml prior to plerixafor was 4.5 (range 0–25)
and 12 hours post plerixaforwas 11.5 (range 0–50).Themedian num-
ber harvestedwas 4.61106CD341 cells/kg (range0.08–9.37). 41%
of patients successfully collected$ 5106 CD341 cells/kg and 74%
collected $ 2 106 CD341 cells/kg. PB CD341 correlated with
CD341 harvested on a daily basis (p \0.0001). PB CD341 pre
and post plerixaforwas able to predict success of collection (see table).
% success % successPB CD341 cells/ml
$2  106 CD341
cells/kg
$5  106
CD341 cells/kgPre-Plerixafor
\5 56% 25%
5–10 100% 64%Post Plerixafor
\5 15% 8%
5–10 83% 8%
.10 97% 69%Conclusion: The combination of plerixafor and G-CSF effec-
tively mobilizes CD341 cells in the majority of pts, in whom a prior
mobilization has failed. PB CD341 remains an important predictor
of CD341 harvested. PB CD341 pre-plerixafor of $5 cells/ ml is
associated with a 100% success rate.189
USE OF SECOND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANS-
PLANTS FOR THE TREATMENT OF MULTIPLE MYELOMA
Harris, P.J., Ririe, D.W. San Antonio Military Medical Center South,
Lackland AFB, TX
Introduction: In patientswith newly diagnosedmultiplemyeloma
who are candidates for autologous stem cell transplant (ASCT), it is
often recommended to proceed straight to ASCT after a response
to initial induction therapy as a way of prolonging progression freesurvival compared to chemotherapy alone. Second (tandem) ASCTs
have been routinely performed in patients with less than a very good
partial response to first transplant, since data has shown improved
survival in this subset of patients. We were interested in reviewing
the number of patients who had received single or tandem ASCTs
formultiplemyeloma, and to evaluate factors influencing thedecision
of whether or not to proceed to a second ASCT.
Methods: This is a single institution retrospective review of pa-
tients who have received an ASCT for multiple myeloma from 1
Jan 2000 until 15 April 2008 at San AntonioMilitaryMedical Center
South in San Antonio, TX. Data was collected regarding patient age,
stage, performance status, cytogenetics, lactate dehydrogenase, beta
-2- microglobulin and albumin levels at diagnosis, treatment given,
number of cells harvested and number and type of transplants
received as well as response to each transplant.
Results: Seventeen of 81 patients (21%)who received oneASCT for
the diagnosis of multiple myeloma went on to receive a second ASCT.
Discussion: Seventy-nine percent of patients at our institution
during the specified times did not receive a tandem ASCT for mul-
tiple myeloma. Patient and disease factors which may have influ-
enced the decision of whether to proceed to a second ASCT are
discussed. Since many patients do not receive the second transplant,
and with the cost of and space required to store unused harvested
cells as well as the time and effort required of patients to collect
enough cells for two transplants, this data may help reduce initial
over collection of hematopoietic stem cells.190
SELECTIVE T-CELL IMMUNOTHERAPY FOR B-CELL LYMPHOMA UNDER
HYPOXIA
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Many tumors harbor chronic and intermittent hypoxic cellular
niches giving a survival advantage to malignant cells including cancer
stem cells. To achieve a successful immunotherapeutic response, T
cellsmust overcome physiological challenges specific to the tumormi-
croenvironment such as hypoxia. To exploit the hypoxic tumormicro-
environment, we introduce a new approach that exploits hypoxia as
a condition for T-cell activation. In addition, this approach may be
used to limit off-target effects to normal cells expressing antigen under
normoxia. We demonstrate that a chimeric antigen receptor (CAR),
which is specific forCD19, expressed onmalignant and normal B cells,
can be conditionally expressed in a strictly oxygen-sensitive manner.
Using the Sleeping Beauty transposon/transposase system, we can
achieve stable, persistent CAR transgene expression from DNA plas-
mids without the expense and complexity of retroviral production.
Cell surface expressionof ourCAR is high at 1%O2 andnot detectable
at 20%O2. This oxygen-sensitive CAR is designed to deactivate when
Tcells circulate out of hypoxic tumormicroenvironments tominimize
deleterious off-target effects in vivo. When supplemented with one or
more survival factors and/or homing receptors, this approach to CAR
expression has the advantage of transforming hypoxia from an adverse
factor to a T-cell triggering mechanism. This is expected to be of
broad interest as investigators implement T-cell immunotherapy to
eliminate tumors from the hypoxic niche aswell as develop approaches
that limit T-cell targeting within desired microenvironments thereby
decreasing the possibility of inadvertent targeting of normal tissues.191
CONTINUED M PROTEIN RESPONSES BEYOND DAY 100 AFTER AUTOLO-
GOUS TRANSPLANTATION FOR MYELOMA: IMPLICATIONS FOR POST
TRANSPLANT STRATEGIES
Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S., Buadi, F.K.,
Dingli, D., Rajkumar, S.V., Litzow, M.R., Gertz, M.A. Mayo Clinic,
Rochester, MN
Background: Patients undergoing autologous stem cell trans-
plantation (SCT) for myeloma usually undergo disease evaluation
approximately 100 days after the SCT. Decisions regarding post
Poster Session-I 71transplant consolidation strategies such as tandem transplantation
and maintenance therapies are usually taken at the time of this eval-
uation. It is not clear how often patients continue to have a drop in
their M protein after day 100 in the absence of additional therapy.
Methods: From among patients who underwent SCT for mye-
loma, we retrieved the day 100 (71–130 days) post-transplant para-
protein results and compared those values to the lowest subsequent
values reached prior to any additional therapy. There were 526 pa-
tients with serum or urine monoclonal protein studies available
from the day 71–130 time period after SCT and were considered
for the study.
Results: There were 338 patients who had an M protein that was
quantified on their serum or urine protein electrophoresis during the
day 100 evaluation. Of these, 199 patients (59%) had further reduction
of the M protein after day 100. Although these patients had a longer
time to progression compared to those with no further decrease after
day 100 (19.1 mos vs. 16.3 mos; P 5 0.009), there was no differences
in theoverall survival post transplant.Among526patients inwhomase-
rum or urine immunofixation result was available at the day 100 evalu-
ation, 66 (13%) were negative for both. Among the remaining 460
patients, 101 patients (22%) subsequent to the d100 evaluation became
immunofixationnegative in serumandurine.Thedelayed IFEnegative
patients performed as well as their early IFE negative counterparts, i.e.
a superior time to progression andoverall survival from transplantation
Conclusions: Continued paraprotein responses (decrease in se-
rum or urine M protein or conversion of immunofixation positive
to negative) are seen in 53% of patients with myeloma undergoing
single SCTbeyond the first 4months after SCT, including an immu-
nofixation negative state, which predicts for superior outcome. This
needs to taken into consideration, when assessing the impact of post
transplant interventions and when making clinical decisions regard-
ing use of additional therapies post SCT.192
SAFETY AND EFFICACY OF THE BUSULFAN, CYCLOPHOSPHAMIDE AND
ETOPOSIDE PREPARATIVE REGIMEN (BUCYE) FOR AUTOLOGOUS HEMA-
TOPOIETIC STEM CELL TRANSPLANT (AUTOHSCT) IN PATIENTS WITH
ADVANCED AGGRESSIVE NHL (AA-NHL) OVER THE AGE OF 60 YEARS
Borate, U., Vaughan, W. University of Alabama at Birmingham, Bir-
mingham, AL
Highdose chemotherapy followedby autoHSCTis the standardof
care for suitable patients with AA-NHL after failure of primary ther-
apy.We have previously reported an improvement in overall survival
(OS) and progression-free survival (PFS) in patients with AA-NHL
treated with the BuCyE preparative regimen and autoHSCT when
pharmacokinetics directed IV Busulfan was substituted for oral Bu-
sulfan in this regimen. Since this improvement was predominantly
due to reduced regimen related toxicity, we increased the upper limit
of age eligibility from 60 years of age to 72 years. Between September
2003 and June 2008, 23 patients between the ages of 60 and 72 with
intermediate and high-risk aggressive NHL underwent autoHSCT
using the BuCyE regimen. Out of the 23 patients between the ages
of 60 and 72, 12 were male and 11 were female. The median age
was 64 with a minimum age of 61 and a maximum age of 72. 18 pa-
tients had diffuse large B cell lymphoma, 8 were transplanted after
their first relapse, 6 after their first complete remission (CR) and 2 af-
ter their second relapse. Two patients hadmantle cell lymphoma and
were transplanted in their second CR. Two patients had follicular
lymphoma with aggressive transformation and were transplanted in
their secondCR.One patient had Burkitt’s lymphoma andwas trans-
planted in first relapse. Eight patients out of the 23 had relapses. Six of
the eight relapsed within a year of autoHSCT, the other two relapsed
at 18 months and 42 months respectively. Ten patients died, three
from regimen related toxicity, five from relapse, and two from other
causes. Twelve patients (52 %) are alive and disease free with follow
up from 3 to 63months from date of transplant, with a median follow
up of 24months. The projected long term disease free survival by the
Kaplan Meier life table analysis is 31%.The pharmacokinetics di-
rected IV Busulfan, Cyclophosphamide and Etoposide Preparative
Regimen for autoHSCT is a reasonable regimen to attempt long-
term survival in patients with Advanced Aggressive NHL (AA-
NHL) over the age of 60 years.193
NON-MYELOABLATIVE CONDITIONING AND ALLOGENEIC TRANSPLAN-
TATION FOR MULTIPLE MYELOMA
Osman, K., Elliott, B.,Mandeli, J., Scigliano, E., Ross-Dodds, V., Isola, L.,
Grosskreutz, C. The Mount Sinai Medical Center, New York, NY
Autologous stem cell transplantation (ASCT) increases survival in
multiple myeloma (MM) but is not curative. Allogeneic transplanta-
tion (alloSCT) carries a lower relapse risk, attributed to a graft-ver-
sus-myeloma effect, but a greater transplant-related mortality
(TRM). Nonmyeloablative (NMA) conditioning reduces trans-
plant-related toxicity. Our group previously reported on 90 patients
conditioned with total body irradiation (TBI), fludarabine, and an-
tithymocyte globulin (ATG). Results were encouraging when used
during first remission in low-risk patients, but less-so in advanced
or resistant disease.We performed a retrospective analysis of 20 pre-
viously-treated MM patients who underwent NMA alloSCT from
2000–06. The median age was 52.5 (37.2–68.0) years. Twenty per-
cent had ISS stage 2 or 3 disease, and 25% had poor cytogenetics.
Seventeen patients received one or more ASCTs, but eleven still
had active disease prior to alloSCT. Fourteen allo-recipients had
matched-related and six had matched-unrelated donors. Median
time from diagnosis to alloSCT was 22.9 (12.2–139.6) months. Pa-
tients underwent conditioning with ATG plus fludarabine for 4
days and 1 dose of TBI. All received immunosuppression and antimi-
crobial prophylaxis. Patients were followed for amedian of 40.5 (0.6–
91.1) months. Median time to engraftment (ANC. 500) was 5 days.
At day 100, 50% had achieved CR, disease-related mortality was
15%, and TRM 10%. Median OS was 21 (0.6–92) months and pro-
gression-free survival (PFS) 6.6 (0.6–92) months. Both 3-year OS
and 2-year PFS were 24%. OS survival was significantly greater for
patients younger than 52 years of age (27 vs. 8 mo, p 5 0.03), and
there was a trend toward greater OS for those with beta-2 microglo-
bulin less than 2.5 mg/l (27 vs. 8 mo, p 5 0.08). Donor type and Ig
type had no significant effect on survival. Our case series suggests
benefit of NMA alloSCT in refractory MM. Randomized trials
must be performed to confirm and further qualify this benefit.194
AN ANALYSIS OF THE CHARGES ASSOCIATED WITH PERIPHERAL BLOOD
HEMATOPOIETIC PROGENITOR CELL (HPC) MOBILIZATION, COLLEC-
TION AND CRYOPRESERVATION IN PATIENTS WITH LYMPHOMAS UN-
DERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION
Walters, K.H., Hosing, C., Smith, V.R., Rhodes, B.A., Thompson, R.C.,
Qazilbash, M.H., McMannis, J.D., Alousi, A., De Lima, M.,
Kebriaei, P., Giralt, S., Khouri, I., Champlin, R.E., Popat, U.R. The Uni-
versity of Texas M.D. Anderson Cancer Center, Houston, TX
Introduction: HPC may be mobilized with cytokines alone or
with chemotherapy followed by cytokines. The HPC yield is higher
and the failure rate is lower with chemomobilization. Although a cell
dose of 2m CD341 cells/kg is considered adequate, some authors
have shown patients (pts) who receive\5m CD 341 cells /kg have
higher resource utilization post transplant. This study was to analyze
the costs associated with HPC chemo mobilization.
Patients and Methods: 149 pts with non-Hodgkin’s (n 5 101)
and Hodgkin’s (n 5 48) lymphomas who underwent HPC chemo-
mobilization from 1/03 and 12/04 were analyzed. Patients who col-
lected\2m CD341 cells /kg in 4 leukapheresis procedures were
called failures. Estimated costs were divided into preapheresis,aphe-
resis, and postapheresis costs.
Results: 133 pts underwent chemo mobilization. Chemotherapy
regimen was ifosfamide, etoposide, G-CSF, 6 rituximab in 98
(74%) pts. The average inpatient stay was 6 days (3–28). 24 pts re-
quired readmission for chemotherapy complications, median of 5
days (1–12). Patients received G-CSF for a median of 14 days (6–
34). Average number of days on oral antibiotics was 9 (0–16). For
successful mobilizers, the median number of apheresis procedures
required to reach target HPC dose of 5m CD341 cells/kg was 2
(1–7). 30 pts failed to collect adequate HPC on the 1st attempt. Of
those, 12 pts underwent a BM harvest ($2389/harvest), 4 were remo-
bilized with chemotherapy (1 mobilized successfully), 4 pts under-
went an allogeneic transplant ($250k–$500k/transplant) and 3 pts
underwent an autologous transplant with suboptimal cell dose (all
had prolonged time to engraftment and 1 pt required an allogeneic
